19Aug 2023
Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook

Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook

Chronic obstructive pulmonary disease (COPD) is a complex inflammatory lung condition causing significant patient burden and healthcare costs. While current treatments like inhalers provide relief, many patients experience symptoms, exacerbations, and declining lung function. Neutrophilic inflammation is common, but 20–40% have type 2 inflammation. Addressing this unmet need requires targeted therapies based on evolving COPD understanding, including epithelial alarmins. This review outlines the treatment landscape, unmet needs, type 2 inflammation, potential biomarkers, and rationale for novel therapies.

  • #critical care

Like

Save

Share